Kartawiadi L, Vercauteren M P, Van Steenberge A L, Adriaensen H A
Department of Anesthesiology, University Hospital Antwerp, Belgium.
Reg Anesth. 1996 May-Jun;21(3):191-6.
The purpose of this investigation was to evaluate the effectiveness and side effects of combined spinal-epidural (CSE) injection of a bupiv-acaine-sufentanil-epinephrine mixture during labor as compared with epidural analgesia alone.
In a randomized trial, 63 parturients presenting for vaginal delivery received either epidural analgesia (10 mL) with 12.5 mg bupivacaine plus 10 micrograms sufentanil and 12.5 micrograms epinephrine or CSE analgesia with a single subarachnoid injection of 1 mg bupivacaine plus 5 micrograms sufentanil and 25 micrograms epinephrine (total volume, 2.5 mL). For this purpose a 29-gauge BD-Quincke spinal needle was used. All subsequent top-ups consisted of 10 mL of the mixture, as used for the patients who received epidural analgesia only.
Thirteen patients delivered without requesting a second injection. The time required to obtain satisfactory analgesia (visual analog score < or = 2.5 and/or > 50% improvement) was significantly shorter for those who received the subarachnoid mixture than for the epidural analgesia group (4.0 +/- 0.4 vs 10.4 +/- 0.5 minutes, respectively, P < .001). The duration of analgesia was longer for the CSE group (137.4 +/- 11.5 vs 106.4 +/- 11.8 minutes, P < .05), with more patients being pain-free for longer than 150 minutes (40 vs 8%, P < .05). Less bupivacaine was consumed in the group receiving the subarachnoid mixture (21.6 +/- 2.0 vs 30.7 +/- 2.1 mg, P < .01). Pruritus was more common following subarachnoid than following epidural injection of sufentanil (53.1 vs 25.8%, P < .05). Other side effects related to the injected drugs, such as motor impairment, hypotension, or nausea or vomiting, were not observed. Although all blocks were uneventful, moderate headache compatible with postdural puncture headache occurred in two patients of the CSE group, which necessitated a blood patch after 5 days.
The CSE mixture induced long-lasting analgesia, with fast onset and without motor block or hypotension. Pruritus and headache were the major drawbacks of this technique.
本研究旨在评估分娩期间联合蛛网膜下腔 - 硬膜外(CSE)注射布比卡因 - 舒芬太尼 - 肾上腺素混合液与单纯硬膜外镇痛相比的有效性及副作用。
在一项随机试验中,63例计划经阴道分娩的产妇,其中一组接受含12.5mg布比卡因、10μg舒芬太尼和12.5μg肾上腺素的硬膜外镇痛(10mL),另一组接受蛛网膜下腔单次注射1mg布比卡因、5μg舒芬太尼和25μg肾上腺素(总体积2.5mL)的CSE镇痛。为此使用了29号BD - Quincke腰麻针。所有后续追加剂量均为10mL上述混合液,与仅接受硬膜外镇痛的患者所用相同。
13例患者未要求第二次注射即分娩。获得满意镇痛效果(视觉模拟评分≤2.5分和/或改善>50%)所需时间,接受蛛网膜下腔混合液的患者明显短于硬膜外镇痛组(分别为4.0±0.4分钟和10.4±0.5分钟,P<0.001)。CSE组镇痛持续时间更长(137.4±11.5分钟对106.4±11.8分钟,P<0.05),无痛持续超过150分钟的患者更多(40%对8%,P<0.05)。接受蛛网膜下腔混合液的组消耗的布比卡因更少(21.6±2.0mg对30.7±2.1mg,P<0.01)。蛛网膜下腔注射舒芬太尼后瘙痒比硬膜外注射更常见(53.1%对25.8%,P<0.05)。未观察到与注射药物相关的其他副作用,如运动障碍、低血压或恶心呕吐。尽管所有阻滞过程均顺利,但CSE组有2例患者出现符合腰穿后头痛的中度头痛,5天后需要进行血补丁治疗。
CSE混合液诱导的镇痛效果持久,起效快,且无运动阻滞或低血压。瘙痒和头痛是该技术的主要缺点。